抑郁和焦虑障碍患者在COVID-19大流行前后的精神药物处方:一项多国网络研究
该多国网络研究纳入六个国家九个数据库2016至2021年抑郁或焦虑障碍患者的电子病历与理赔数据,采用中断时间序列分析发现大流行期间精神药物处方率出现初始上升后逐渐下降或持续升高两种模式,且在部分数据库中年轻患者焦虑药物处方率持续上升。
要点
- 大流行初期抗精神病药等处方率出现初始上升,随后逐渐下降至反事实水平。
- 部分数据库中焦虑药物和抗精神病药处方率立即升高且后续斜率无变化。
- 在MDCD_US和IQVIA_US中,小于25岁患者两类障碍的焦虑药物处方率持续上升。
核心结论
- 研究揭示大流行初期之后精神药物处方率持续升高,强调加强心理健康支持和定期审查该患者群体精神药物使用的重要性。
研究设计与样本
- 多国网络研究,纳入六个国家(法国、德国、意大利、英国、韩国和美国)九个数据库2016至2021年抑郁或焦虑障碍患者的电子病历和理赔数据。
- 采用中断时间序列分析评估大流行与精神药物处方的关联,并对性别和年龄组进行分层分析。
主要发现
- 2016年1月1日至2020年12月31日,年均识别抑郁障碍患者16 567 914例(女性10 820 956例[65.31%],男性5 746 958例[34.69%])和焦虑障碍患者15 988 451例(女性10 688 788例[66.85%],男性5 299 663例[33.15%])。
- 抑郁障碍和焦虑障碍患者多数年龄为45-64岁,种族数据不可用。
- 第一种模式:大流行开始时处方率初始上升,例如MDCD_US中抑郁障碍患者的抗精神病药(率比[RR] 1.077,95%CI 1.055-1.100),随后逐渐下降至反事实水平(RR 0.990,95%CI 0.988-0.992)。
- 第二种模式见于四个数据库中抑郁障碍患者的焦虑药物和两个数据库中焦虑障碍患者的抗精神病药,表现为立即升高(例如IQVIA_UK中焦虑障碍患者的抗精神病药:RR 1.467,95%CI 1.282-1.675),后续斜率无变化(RR 0.985,95%CI 0.969-1.003)。
- 在MDCD_US和IQVIA_US中,两种障碍小于25岁患者的焦虑药物处方率持续上升。
临床怎么用
- 原文未据此给出推荐。
局限性
- 有亲身经历的人未参与研究和写作过程。
- 种族数据不可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with mental health conditions were potentially more vulnerable than others to the neuropsychiatric effects of the COVID-19 pandemic and the global efforts taken to contain it. The aim of this multinational study was to examine the changes in psychotropic drug prescribing during the pandemic among people with depressive and anxiety disorders. METHODS: This study included electronic medical records and claims data from nine databases in six countries (France, Germany, Italy, the UK, South Korea, and the USA) of patients with a diagnosis of depressive or anxiety disorders between 2016 and 2021. The outcomes were monthly prevalence rates of antidepressant, antipsychotic, and anxiolytic drug prescribing. The associations between the pandemic and psychotropic drug prescribing were examined with interrupted time series analyses for the total sample and stratified by sex and age group. People with lived experience were not involved in the research and writing process. FINDINGS: Between Jan 1, 2016 and Dec 31, 2020, an average of 16 567 914 patients with depressive disorders (10 820 956 females [65·31%] and 5 746 958 males [34·69%]) and 15 988 451 patients with anxiety disorders (10 688 788 females [66·85%] and 5 299 663 males [33·15%]) were identified annually. Most patients with depressive disorders and anxiety disorders were aged 45-64 years. Ethnicity data were not available. Two distinct trends in prescribing rates were identified. The first pattern shows an initial surge at the start of the pandemic (eg, antipsychotics among patients with depressive disorders in MDCD_US (rate ratio [RR] 1·077, 95% CI 1·055-1·100), followed by a gradual decline towards the counterfactual level (RR 0·990, 95% CI 0·988-0·992). The second pattern, observed in four databases for anxiolytics among patients with depressive disorders and two for antipsychotics among patients with anxiety disorders, shows an immediate increase (eg, antipsychotics among patients with anxiety disorders in IQVIA_UK: RR 1·467, 95% CI 1·282-1·675) without a subsequent change in slope (RR 0·985, 95% CI 0·969-1·003). In MDCD_US and IQVIA_US, the anxiolytic prescribing rate continued to increase among patients younger than 25 years for both disorders. INTERPRETATION: The study reveals persistently elevated rates of psychotropic drug prescriptions beyond the initial phase of the pandemic. These findings underscore the importance of enhanced mental health support and emphasise the need for regular review of psychotropic drug use among this patient group in the post-pandemic era. FUNDING: University Grants Committee, Research Grants Council, The Government of the Hong Kong Special Administrative Region.
引用
- Luo H, Chai Y, Li S, et al. Psychotropic drug prescribing before and during the COVID-19 pandemic among people with depressive and anxiety disorders: a multinational network study. Lancet Psychiatry. 2024. PMID: 39241791. doi:10.1016/S2215-0366(24)00245-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。